Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy

Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer cells.

It blocks the CD47 “don’t eat me” signal, enabling macrophages to recognize and eliminate malignant cells more effectively.

Ozuriftamab has been studied primarily in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), showing potential in combination therapies.

Initial studies revealed a manageable safety profile, although treatment-emergent cytopenias and infusion-related reactions were noted and require monitoring.

By inhibiting CD47, Ozuriftamab restores innate immune surveillance, potentially overcoming tumor immune evasion.

Magrolimab is a groundbreaking therapeutic antibody developed to target CD47, a protein frequently overexpressed on the surface of cancer cells. Known as the "don't eat me" signal, CD47 helps cancer cells avoid detection and destruction by the immune system. By blocking this signal, Magrolimab facilitates the immune system's ability to identify and destroy cancerous cells.

Initially developed by Forty Seven, Inc., Magrolimab gained significant attention following its acquisition by Gilead Sciences. The drug has been explored across a range of malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and diffuse large B-cell lymphoma (DLBCL). Though some trials, like ENHANCE, were discontinued, Magrolimab remains a focal point for ongoing research due to its novel mechanism and therapeutic promise.

Magrolimab functions by inhibiting CD47, a transmembrane protein expressed on both normal and cancerous cells. CD47 interacts with signal regulatory protein alpha (SIRPα) on macrophages, transmitting a "don't eat me" signal that prevents phagocytosis. By blocking this interaction, Magrolimab reactivates the innate immune system, enabling macrophages to engulf and destroy cancer cells.

This targeted approach has shown promise in hematologic malignancies and solid tumors, particularly when combined with other agents like azacitidine. Preclinical studies suggest that Magrolimab synergizes with these therapies to enhance anti-tumor activity.

Acute Myeloid Leukemia (AML): Magrolimab has been studied extensively in AML, particularly in patients with TP53 mutations, a group with limited treatment options.

Myelodysplastic Syndromes (MDS): The enhance trial explored Magrolimab combined with azacitidine in higher-risk MDS. While discontinued, this research has informed subsequent investigations.

Diffuse Large B-Cell Lymphoma (DLBCL): Ongoing trials are evaluating the efficacy of Magrolimab in DLBCL, highlighting its potential in B-cell malignancies.

Solid Tumors: Early-stage studies have demonstrated the potential of Magrolimab in treating solid tumors by overcoming immune resistance mechanisms.

Biosimilars provide an invaluable resource for advancing research into innovative therapies like Magrolimab. Our Magrolimab (Anti-CD47) Biosimilar Antibody offers a high-quality, research-grade alternative for preclinical investigations.

Biosimilars are biologic products designed to be highly similar to approved reference drugs, offering comparable safety and efficacy. They are critical tools in accelerating drug development and expanding access to cutting-edge therapies.